In-Vivo Cell Engineering for Regenerative Medicine

Conventional cell therapy generally modifies, expands, or differentiates cells outside the body before transplantation. In-vivo cell engineering instead delivers biological instructions to selected cells where they already reside. The instructions may alter cell identity, activate a repair programme, or confer a temporary therapeutic function. These approaches share a delivery problem, but they do not constitute one technology and should not be assumed to have the same risks or evidence base. [1] [2]

Direct Lineage Reprogramming

Direct reprogramming, also called transdifferentiation, uses combinations of lineage-defining transcription factors, regulatory RNAs, or other signals to move a differentiated cell toward another identity without first creating a pluripotent stem cell. [1] Avoiding a pluripotent intermediate may reduce some risks associated with uncontrolled pluripotent-cell growth, but it does not remove the possibility of incomplete, heterogeneous, or off-target conversion. [1] [2]

A foundational mouse study delivered three developmental regulators to adult pancreatic exocrine cells and produced insulin-expressing cells with several beta-cell characteristics. [3] In the injured mouse heart, delivery of cardiac transcription factors converted some resident fibroblasts toward cardiomyocyte-like states and was associated with reduced scar area and improved cardiac function. [4] Later work using a non-integrating Sendai virus increased reprogramming efficiency and reported functional improvement after myocardial infarction in mice. [5]

Other Tissue Contexts

Neural studies have tested whether resident glial cells can be redirected toward neuronal identities. Viral expression of neuronal factors generated induced neurons in the adult rodent brain, establishing lineage conversion as an in-vivo possibility. [6] Interpretation requires careful lineage tracing because changes in marker expression alone do not prove that a starting cell became a mature, integrated neuron. Reviews of the field identify origin tracing, electrophysiological maturity, circuit integration, and reproducibility as necessary evidence. [2]

In the liver, transcription-factor delivery converted activated myofibroblasts toward hepatocyte-like cells and reduced fibrosis in mouse models. [7] This illustrates a proposed two-part benefit: reduce a disease-driving cell population while producing a cell type involved in tissue function. Whether both effects persist, scale, and remain selective in human chronic disease is unresolved. [1] [7]

Engineering Therapeutic Function Without Changing Lineage

Not all in-vivo engineering attempts to create a new cell type. In a mouse model of cardiac injury, CD5-targeted lipid nanoparticles delivered modified mRNA encoding a fibroblast-activation-protein CAR to T cells. The resulting CAR expression was transient, and treatment reduced fibrosis and improved measured cardiac function in that model. [8] This is functional programming of immune cells rather than direct conversion of one tissue lineage into another.

Transient mRNA can limit the duration of an engineered programme and avoids genomic integration, but it also makes exposure dependent on delivery efficiency and RNA persistence. The cardiac study was a mouse proof of concept; it did not establish regenerative efficacy, dosing, or safety in humans. [8]

What Must Be Engineered

Delivery and Safety Constraints

Delivery determines which organs and cell populations are exposed. Viral vectors can provide efficient gene transfer but differ in tissue tropism, payload capacity, persistence, and immune recognition. Non-viral systems such as lipid nanoparticles can support transient RNA expression, although their biodistribution and cell-type targeting also require engineering. [5] [8] Results obtained with local injection into an injured organ cannot be generalized to systemic delivery.

Cell identity is embedded in regulatory networks rather than controlled by a single marker. Forced expression can therefore yield intermediate states, and converted cells may differ from native cells in maturation, metabolism, electrophysiology, or long-term stability. [1] [2] Additional concerns include inflammation, disruption of beneficial repair cells, arrhythmia for cardiac applications, and tumour formation if growth or pluripotency programmes are insufficiently controlled. [2] [9]

Relationship to Ageing Biology

Ageing changes the abundance, responsiveness, and molecular state of candidate target cells, as well as the inflammatory and extracellular environment in which conversion must occur. A protocol effective in young or acutely injured mice may therefore behave differently in old tissue with fibrosis, immune dysfunction, or depleted progenitor populations. [1] Evidence that reprogrammed cells can repair a specific experimental injury is not evidence that organismal ageing has been reversed.

Partial pluripotency-factor reprogramming is a related but separate research area. It seeks to alter age-associated cellular state while retaining the original lineage, whereas direct lineage reprogramming deliberately changes identity. Animal studies of partial reprogramming also highlight the importance of factor selection, timing, tissue targeting, and tumour risk. [9]

Evidence Quality and Interpretation

The field has multiple independent proofs of biological principle in rodents, spanning pancreas, heart, brain, liver, and immune-cell programming. [3] [4] [6] [7] [8] These studies support the proposition that adult cells can be instructed inside an organism; they do not establish that the resulting cells are equivalent to native cells in every relevant property.

Translation remains limited by species differences, artificial injury models, variable lineage-tracing methods, and delivery systems that may not scale safely to human organs. [1] [2] The most informative future studies would combine rigorous fate mapping, single-cell molecular analysis, direct functional testing, long follow-up, and evaluation in aged and large-animal models before clinical claims are made.

What the Research Does Not Establish

• It does not establish a general method for regenerating any organ; each target tissue requires a distinct cell source, programme, and delivery system. [1]
• It does not show that marker expression alone demonstrates mature or integrated cell function. [2]
• It does not show that avoiding ex-vivo manufacture removes immune, genomic, tumour, or off-target risks. [1] [9]
• It does not establish rejuvenation or lifespan extension; the cited studies test tissue-specific repair or disease outcomes. [3] [4] [7] [8]

Summary

In-vivo cell engineering treats resident cells as the substrate for a therapy. Direct reprogramming attempts to replace a depleted lineage, while transient functional programming can recruit existing cells to modify a pathological tissue process. Rodent studies demonstrate that both concepts are biologically feasible. [3] [4] [7] [8] Their clinical value will depend on precise delivery, faithful cell states, appropriate integration, controllable duration, and evidence that tissue benefit exceeds the risks of altering cells within the body. [1] [2]

References

1. Wang, H. et al. "Direct cell reprogramming: approaches, mechanisms and progress." Nature Reviews Molecular Cell Biology (2021). https://doi.org/10.1038/s41580-021-00335-z
2. Heinrich, C., Spagnoli, F. M. & Berninger, B. "In vivo reprogramming for tissue repair." Nature Cell Biology (2015). https://doi.org/10.1038/ncb3108
3. Zhou, Q. et al. "In vivo reprogramming of adult pancreatic exocrine cells to beta-cells." Nature (2008). https://doi.org/10.1038/nature07314
4. Qian, L. et al. "In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes." Nature (2012). https://doi.org/10.1038/nature11044
5. Miyamoto, K. et al. "Direct In Vivo Reprogramming with Sendai Virus Vectors Improves Cardiac Function after Myocardial Infarction." Cell Stem Cell (2018). https://doi.org/10.1016/j.stem.2017.11.010
6. Torper, O. et al. "Generation of induced neurons via direct conversion in vivo." Proceedings of the National Academy of Sciences (2013). https://doi.org/10.1073/pnas.1303829110
7. Song, G. et al. "Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis." Cell Stem Cell (2016). https://doi.org/10.1016/j.stem.2016.01.010
8. Rurik, J. G. et al. "CAR T cells produced in vivo to treat cardiac injury." Science (2022). https://doi.org/10.1126/science.abm0594
9. Ocampo, A. et al. "In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming." Cell (2016). https://doi.org/10.1016/j.cell.2016.11.052